Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities research analysts at Atb Cap Markets reduced their FY2024 earnings per share (EPS) estimates for shares of Curaleaf in a report issued on Thursday, November 7th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.24) per share for the year, down from their previous estimate of ($0.21). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf's Q4 2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.14) EPS.
A number of other brokerages also recently commented on CURLF. Cormark downgraded Curaleaf from a "moderate buy" rating to a "hold" rating in a research report on Thursday. Needham & Company LLC reiterated a "buy" rating and set a $6.25 price target on shares of Curaleaf in a research note on Thursday, August 8th.
Get Our Latest Research Report on Curaleaf
Curaleaf Stock Performance
Shares of CURLF stock traded down $0.47 during trading hours on Monday, reaching $1.66. 3,126,765 shares of the company's stock were exchanged, compared to its average volume of 702,513. Curaleaf has a fifty-two week low of $1.64 and a fifty-two week high of $6.40. The company has a quick ratio of 0.50, a current ratio of 1.09 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $1.08 billion, a P/E ratio of -5.72 and a beta of 0.86. The business has a fifty day moving average price of $2.95 and a 200-day moving average price of $3.77.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
